Nephrotoxicity from Immune Checkpoint Inhibitors
renalfellow5
Published on Oct 29, 2022
Jose Manuel Monroy Trujillo, MD
Assistant Professor; Division of Nephrology, Johns Hopkins Hospital
Associate Program Director; Division of Nephrology, Johns Hopkins Hospital
DOM Grand Rounds 10/13/2022
Category
Add to
Please Sign In or Create Account to use this feature!
Flag Video
Please Sign In or Create Account to use this feature!
Rate video
Please Sign In or Create Account to use this feature!
Rate video
Please Sign In or Create Account to use this feature!
Up next
Autoplay
Autoplay
Recommended
-
Watch Later
45:18Onconephrology Updates: Immune Checkpoint Inhibitors and Kidney Injury
17 views 834 days ago -
Watch Later
53:09SGLT2 Inhibitors in Type 2 DM: A Cardiorenal "Game-Changer"
20 views 1265 days ago -
Watch Later
29:13 -
Watch Later
01:20:15Harnessing the Power of Immune Tolerance in Living-Donor Kidney Transplant
16 views 792 days ago -
Watch Later
![Abbal Koirala, MD - Rituximab in the management of MCD and immune mediated FSGS]()
29:03Abbal Koirala, MD - Rituximab in the management of MCD and immune mediated FSGS
17 views 787 days ago
